Clinical Trials Logo

Severe Alcoholic Hepatitis clinical trials

View clinical trials related to Severe Alcoholic Hepatitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06155760 Not yet recruiting - Clinical trials for Severe Alcoholic Hepatitis

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Start date: November 25, 2023
Phase: N/A
Study type: Interventional

Severity of alcoholic hepatitis is defined by Maddrey's discriminant function, value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis with one month mortality of 30%-50%. Prednisolone (40 mg/day) given orally should be considered to improve 28-day mortality in patients with severe AH. Abstinence is key to long-term survival. According to current protocol, we discontinue the treatment after 28 days but only 15 % patient is achieving the DF < 32 after 28 days of treatment. The aim of this study is to evaluate the role of extended low dose prednisolone (10mg) in achieving remission by day-90 in steroid responsive severe alcoholic hepatitis.

NCT ID: NCT02485106 Not yet recruiting - Clinical trials for Severe Alcoholic Hepatitis

Rifaximin Use in Severe Alcoholic Hepatitis

Start date: July 2015
Phase: Phase 3
Study type: Interventional

This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.